Rationale: Myocardial infarction (MI) results in remodeling of the myocardium and the extracellular matrix (ECM). Tissue inhibitors of metalloproteinases (TIMPs) are critical regulators of ECM integrity via inhibiting matrix metalloproteinases (MMPs). TIMP2 is highly expressed in the heart and is the only TIMP that, in addition to inhibiting MMPs, is required for cell surface activation of pro-MMP2. Hence, it is difficult to predict the function of TIMP2 as protective (MMP-inhibiting) or harmful (MMP-activating) in heart disease. Objective: We examined the role of TIMP2 in the cardiac response to MI. Methods and Results: MI was induced in 11-to 12-week-old male TIMP2 ؊/؊ and age-matched wild-type mice. Cardiac function was monitored by echocardiography at 1 and 4 weeks post-MI. ECM fibrillar structure was visualized using second harmonic generation and multiphoton imaging of unfixed/unstained hearts. Molecular analyses were performed at 3 days and 1 week post-MI on flash-frozen infarct, periinfarct, and noninfarct tissue. Membrane type 1 (MT1)-MMP levels and activity were measured in membrane protein fractions. TIMP2 ؊/؊ -MI mice exhibited a 25% greater infarct expansion, markedly exacerbated left ventricular dilation (by 12%) and dysfunction (by 30%), and more severe inflammation compared to wild-type MI mice. Adverse ECM remodeling was detected by reduced density and enhanced disarray of fibrillar collagen in TIMP2 ؊/؊ -MI compared to wild-type MI hearts. TIMP2 deficiency completely abrogated MMP2 activation but markedly increased collagenase activity, particularly MT1-MMP activity post-MI. Conclusions: The MMP-inhibitory function of TIMP2 is a key determinant of post-MI myocardial remodeling primarily because of its inhibitory action on MT1-MMP. TIMP2 replenishment in diseased myocardium could provide a potential therapy in reducing or preventing disease progression. (Circ Res. 2010;106:796-808.)
C oronary artery disease is the most common cause of heart failure in Western nations. 1 Myocardial infarction (MI) results in adverse remodeling of the myocardium including the extracellular matrix (ECM). 2 ECM is a dynamic structure which undergoes constant turnover, and its intact structure is essential for optimal cardiac structure and function. Tissue inhibitors of metalloproteinases (TIMPs) play a critical role in regulating the activity of the ECM-degrading enzymes matrix metalloproteinases (MMPs). [3] [4] [5] Four TIMPs have been identified so far (TIMP1 to TIMP4), with TIMP2 and TIMP3 being the highly expressed TIMPs in the heart and TIMP4 showing a tissue-specific expression pattern which includes the heart and the brain. 6 TIMP2 levels have been shown to be altered in patients with different types of heart disease such as pressure overload 7 and atrial fibrillation. 8 In patients with ischemic or idiopathic dilated cardiomyopathy, myocardial protein levels of TIMP2 remained unaltered 9, 10 or increased in end-stage dilated cardiomyopathy patients, 11 whereas plasma analyses revealed a rise in TIMP2 levels in late stages of MI. 12 TIMP2 is unique among TIMPs because, in addition to inhibiting a number of MMPs, it mediates MMP activation. TIMP2 is required for cell surface activation of MMP2 by selectively interacting with membrane type-1 (MT1)-MMP and pro-MMP2, forming a trimolecular complex (MT1-MMP/TIMP2/pro-MMP2) and thereby converting pro-MMP2 (72 kDa) to its active form (62 kDa). 13, 14 MMP2 has been linked to a number of cardiomyopathies. 4, 5, 15 Given this multidimensional biochemical function of TIMP2 (an activator and an inhibitor of MMPs), the impact of altered TIMP2 levels in disease is unpredictable.
In this study, we directly examined the role of TIMP2 in cardiac response to MI by subjecting mice lacking TIMP2 and age-matched wild-type (WT) mice to MI using the left anterior descending artery ligation model. TIMP2 deficiency markedly exacerbated left ventricular (LV) dilation and systolic dysfunction compared to WT mice. TIMP2 Ϫ/Ϫ hearts exhibited excess degradation of the ECM collagen fibers because of enhanced activity of collagenases, particularly MT1-MMP. Activation of pro-MMP2 was completely abrogated in TIMP2 Ϫ/Ϫ hearts. Collectively, the MMP-inhibitory function of TIMP2, but not its MMP-activating function, is critical in the cardiac response to MI.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Experimental Animals and Left Anterior Descending Artery Ligation Model of MI
Male 11-to 12-week-old WT and TIMP2-deficient mice 16 in C57BL/6 background were subjected to MI induced by ligation of the left anterior descending artery as before. 17 All animal experiments were carried out in accordance with Canadian Council on Animal Care Guidelines and regulations of Animal Policy and Welfare committee at University of Alberta, as well as the Guide for the Care and Use of Laboratory Animals published by the NIH.
Echocardiographic Imaging and Infarct Size Measurement
In vivo cardiac function was measured by echocardiography at 1 and 4 weeks post-MI using a Vevo 770 high-resolution imaging system equipped with a 30-MHz transducer (RMV-707B; VisualSonics, Toronto, Canada) as previously described. 18, 19 Infarct size was measured at 1 week post-MI as described previously. 17
Second Harmonic Generation and Multiphoton Imaging
Collagen fibers in unfixed and unstained heart tissue were visualized by using the novel second harmonic generation (SHG) and multiphoton excitation fluorescence (MPEF) microscopy imaging technique as described. 20
Quantification of Fibrillar Collagen
Total fibrillar collagen content was measured using QuickZyme Collagen Assay (QuickZyme Biosciences, Netherlands) according to the instructions of the manufacturer.
Immunohistochemistry
Neutrophil and macrophage staining were performed on formalinfixed heart tissue as before. 4
Western Blot Analysis, Gelatin Zymography, Gelatinase/Collagenase Activity Assays
Gelatin zymography and Western blot analyses were performed as before. 4, 17 Total gelatinase and collagenase activities were measured using EnzChek fluorescent-based activity assays according to the instructions of the manufacturer.
Protein Levels and Activity of MT1-MMP in the Membrane Fraction
Western blot analyses for MT1-MMP, Toll-like receptor-4, and caspase3 were performed on membrane protein fractions as before. 4, 17 Activity of MT1-MMP was measured using Amersham Biotrak activity assay (RPN2637, GE Healthcare) according to the instructions of the manufacturer.
mRNA Expression Analysis
RNA expression analysis was performed by TaqMan RT-PCR as described previously. 4, 21 TaqMan primers and probes used for the reported gene is reported in Online Table I . Expression levels of all genes were normalized to HPRT (hypoxanthine-guanine phosphoribosyltransferase-1), which has been shown to be an appropriate house-keeping gene for myocardial tissue. 22
Statistical Analysis
All statistical analyses were performed using SPSS software (version 10.1; Chicago, Ill). Mortality and rupture incidents were compared using Kaplan-Meier method, and the log rank test for statistical significance in the survival distribution. Comparisons between genotypes were performed using multiple ANOVA test followed by Student-Neuman-Keuls test for multiple comparison testing. Averaged values represent meansϮSEM. Statistical significance is recognized at PϽ0.05.
Results

MI Alters TIMPs Differently in WT Versus TIMP2 ؊/؊ Mice
We first examined whether MI affects TIMP2 mRNA and protein levels in WT hearts. TIMP2 mRNA levels decreased in the infarct area at 3 days ( Figure 1A , ii) followed by a marked increase at 1 week post-MI ( Figure 1A , vi) but increased in the peri-and noninfarct regions at both time points ( Figure 1A , ii and vi). TIMP2 protein levels, however, showed a persistent and significant reduction in the infarct, periinfarct, and noninfarct regions at 3 days and 1 week post-MI compared to sham-operated hearts ( Figure 1B , i and ii). These data raised the question of whether the altered TIMP2 levels could improve or adversely impact the cardiac recovery following MI.
We examined whether absence of TIMP2 triggers upregulation of other TIMPs in the myocardium as a compensatory mechanism. Compared to the corresponding WT myocardium, TIMP1 mRNA levels were higher in sham-operated TIMP2 Ϫ/Ϫ hearts and increased to a significantly greater level in the TIMP2 Ϫ/Ϫ periinfarct at 3 days ( Figure 1A , i) and infarct at 1 week post-MI ( Figure 1A , ii). At the protein level, TIMP1 increased by 10-fold in the infarct and 5-fold in the periinfarct regions of TIMP2 Ϫ/Ϫ compared to a 3-fold increase in WT infarct myocardium at 3 days ( Figure 1B , i and ii). However, at 1 week post-MI, the increase in TIMP1
protein levels was comparable between the two genotypes ( Figure 1B , iii and iv). The mRNA and protein levels for TIMP3 ( Figure 1A [iii and vii] and 1B) and TIMP4 ( Figure  1A [iv and viii] and 1B) changed similarly in both genotypes post-MI, except for a significantly higher TIMP4 protein level in the TIMP2 Ϫ/Ϫ periinfarct myocardium at 1 week post-MI ( Figure 1B , iii and iv). The increase in TIMP1 (and the smaller increase in TIMP4) in TIMP2 Ϫ/Ϫ -MI hearts could compensate for the absence of TIMP2.
TIMP2 Deficiency Increases Severity of Disease Following MI
Following MI, WT and TIMP2 Ϫ/Ϫ mice exhibited a similar rate of survival over the 4-week period (51% versus 48%). Autopsy examination revealed a comparable rate of LV rupture between the 2 genotypes post-MI (41% in WT and 39% in TIMP2 Ϫ/Ϫ ) ( Figure 2B ). Despite the similar survival rates, gross histological analysis of the hearts revealed a larger LV chamber size ( Figure 2C ) and infarct size ( Figure 2D ) in TIMP2 Ϫ/Ϫ compared to WT mice at 1
week post-MI. This indicates greater infarct expansion in TIMP2 Ϫ/Ϫ mice because the initial infarct size at 1 day post-MI was comparable between genotypes (46Ϯ5% in WT and 49Ϯ5% in TIMP2 Ϫ/Ϫ , Pϭ0.15, nϭ6/genotype). In addition, brain natriuretic peptide, a disease marker known to correlate with the degree of LV wall stress, 23 was elevated to a greater extent in the infarct and periinfarct regions of TIMP2 Ϫ/Ϫ hearts at 3 days, and in peri-and noninfarct regions at 1 week post-MI compared to the corresponding WT myocardium ( Figure 2E ). Lung water content, also a marker of severity of post-MI LV dysfunction, was significantly higher in TIMP2 Ϫ/Ϫ compared to WT mice at 1 week post-MI ( Figure 2F ). These data collectively suggest that TIMP2 deficiency enhances the pathological cardiac response to MI.
TIMP2-Deficient Mice Exhibit Greater Ventricular Dilation and Worsening of Systolic Function After MI
We evaluated cardiac function by echocardiography at 1 week ( Figure 3 ) and 4 weeks (Online Table II ) post-MI in WT and TIMP2 Ϫ/Ϫ mice. Sham-operated mice from either genotype served as baseline controls. All parameters representing cardiac structure and function were comparable between sham-operated TIMP2 Ϫ/Ϫ and WT mice ( Figure 3 and Online  Table II ). Representative parasternal long axis images from sham and post-MI hearts show greater LV chamber dilation in TIMP2 Ϫ/Ϫ -MI compared to WT-MI heart ( Figure 3A ). LV end-diastolic volume and end-systolic volume were significantly larger in TIMP2 Ϫ/Ϫ compared to WT mice ( Figure 3C , i and ii), whereas the reduction in ejection fraction was significantly greater in TIMP2 Ϫ/Ϫ compared to WT mice ( Figure 3C , iii). The LV dilation and dysfunction deteriorated more progressively in TIMP2 Ϫ/Ϫ mice by 4 weeks post-MI (Online Table II ). Wall motion score index (WMSI) is a novel and validated method of evaluating regional LV wall motion abnormalities and correlates with the degree of adverse ventricular remodeling post-MI. 19, 24 Sham-operated hearts have a WMSI of 1, indicating intact LV wall motion and contractility. TIMP2 Ϫ/Ϫ hearts had significantly greater wall motion abnormalities at 1 week post-MI compared to WT-MI mice ( Figure 3C , iv), attributable primarily to worsening of midventricular and apical wall motion which extended into the basal anterior/ anterolateral segments in the TIMP2 Ϫ/Ϫ -MI hearts (Online Figure I ). Tissue Doppler images from sham and post-MI hearts illustrate a marked reduction of systolic annular velocity (SЈ), a sensitive measure of systolic function, in the TIMP2 Ϫ/Ϫ -MI compared to WT-MI heart ( Figure 3C ). Overall, TIMP2 deficiency resulted in exacerbated LV dilation, greater wall motion abnormalities, and systolic dysfunction following MI. 
TIMP2 Deficiency Leads to Aberrant ECM Degradation After MI
To determine the underlying mechanism of the adverse LV remodeling and dysfunction in TIMP2 Ϫ/Ϫ -MI mice, we examined whether absence of TIMP2 impacts the post-MI remodeling of the myocardial ECM. We used the SHG and MPEF microscopy to visualize the fibrillar structure of the ECM in unfixed and unstained hearts. Highly ordered fibrillar collagens (types I and III in the myocardium) produce SHG signals, which can be visualized in fresh tissue without the need for exogenous labeling. 20, 25, 26 Other cell types and structures within the tissue generate MPEF because of their autofluorescence characteristics. The SHG emission spectrum shows a strong signal and a narrow peak at 440 nm ( Figure 4A, i) , whereas the autofluorescence signal is very broad and extends across the visible spectrum ( Figure 4A , ii). Representative SHG images showing fibrillar collagen matrix (red) overlaid with the MPEF images of autofluorescence (green) are shown in Figure 4A (iii).
The structural arrangements of the collagen fibers and the fibrillar densities in sham-operated hearts from either genotype were comparable ( Figure 4B) . At 3 days post-MI, WT hearts showed marked disarray and reduced collagen fiber density in the infarct and to a lesser extent in the noninfarct region ( Figure 4B, top row) . Interestingly, TIMP2 Ϫ/Ϫ -MI hearts exhibited strikingly excessive degradation and disarray of the collagen fibers in the infarct and the noninfarct myocardium compared to WT-MI hearts ( Figure 4B , bottom row). The stronger autofluorescence in the infarct areas is likely attributable to accumulated necrotic cells, lipofuscin, and blood-derived pigments. 27 Quantification of the fibrillar collagen revealed lower fibrillar collagen content in the infarct and noninfarct myocardium of both genotypes, whereas the reductions were significantly greater in TIMP2 Ϫ/Ϫ -MI hearts ( Figure  4C ). These data indicate that TIMP2 deficiency leads to more severe degradation and adverse remodeling of the myocardial ECM structure following MI.
Exacerbated Ventricular Dilation and Dysfunction in TIMP2 ؊/؊ -MI Mice Is Associated With Heightened Inflammation
Infiltration of inflammatory cells such as neutrophils and macrophages is an early tissue response to MI which contributes to the subsequent tissue remodeling and disease progression. 28 Staining for neutrophils and macrophages revealed a markedly higher number of these inflammatory cells in the TIMP2-deficient infarct and periinfarct myocardium at 3day and 1 week post-MI ( Figure 5A , i and ii). At 1 week post-MI, the number of neutrophils and macrophages were noticeably reduced in both genotypes compared to 3 days post-MI ( Figure 5A ). To further assess the extent of inflammation, we measured the expression of the inflammatory markers interleukin-6 and monocyte chemotactic protein-1 in these hearts. TIMP2 Ϫ/Ϫ hearts showed a significantly greater increase in interleukin-6 and monocyte chemotactic protein-1 in the infarct and periinfarct regions at 3 days post-MI ( Figure  5B , i), which persisted in the infarct regions at 1 week post-MI ( Figure 5B , ii).
MMP2 Activation Is Abrogated in TIMP2-Deficient Myocardium
Next, we investigated the molecular mechanism for the enhanced ECM degradation in TIMP2-deficient hearts post-MI. TIMP2 can activate or inhibit MMP2 in a dose-dependent manner. 29 MMP2 is produced as a proenzyme (72 kDa), which then undergoes cell surface activation and is cleaved to its active (62-kDa) form. 13, 14 At 3 days post-MI, WT and TIMP2 Ϫ/Ϫ hearts exhibited a similar increase in pro-MMP2 (72 kDa) levels ( Figure 6A and 6B [ii]). Active MMP2 levels (62 kDa) increased significantly in WT hearts, whereas no active MMP2 was detected in the TIMP2 Ϫ/Ϫ myocardium ( Figure 6A and 6B [iii]). MMP9 levels increased similarly in the infarct and periinfarct regions of both genotypes but to a greater degree in the TIMP2 Ϫ/Ϫ noninfarct myocardium ( Figure 6A and 6B) . The increase in MMP2 and MMP9 occurred in the absence of an increase in their mRNA levels in both genotypes (Online Figure II, A) , suggesting involvement of posttranscriptional mechanism(s).
At 1 week post-MI, MMP9 levels were significantly higher in TIMP2 Ϫ/Ϫ infarct and periinfarct regions compared to the corresponding WT myocardium ( Figure 6D and 6E) . Pro-and active MMP2 levels were strikingly elevated in the WT-MI hearts, whereas no active MMP2 was detected in TIMP2 Ϫ/Ϫ hearts ( Figure 6D, 6E [ii], and 6E [iii]) despite a similar increase in MMP2 mRNA levels in both genotypes (Online Figure II, B) . A limitation of the gelatin zymography is that it does not reflect the interaction between the MMPs and TIMPs. We measured total gelatinase activity (using the EnzChek activity assay) and found it to be comparable between the 2 genotypes in all regions of the myocardium at 3 days and 1 week post-MI ( Figure 6D and 6F) . Hence, the greater increase in MMP9 levels in TIMP2 Ϫ/Ϫ -MI hearts is counterbalanced by the lack of MMP2 activation in these hearts, resulting in a similar overall increase in gelatinase activity in TIMP2 Ϫ/Ϫ compared to WT hearts post-MI. These data provide the first in vivo evidence that TIMP2 is a critical molecule essential for MMP2 activation in the myocardium.
Collagenases and MT1-MMP Activity Are Elevated in TIMP2 ؊/؊ -MI Hearts
Because the similar levels of gelatinase activities between TIMP2 Ϫ/Ϫ and WT myocardium could not explain the excess ECM degradation in the former group, we examined the activity of other MMPs. A number of collagenases have been shown to contribute to the progression of heart disease. 4, 5 We found that total collagenase activity increased to a significantly greater level in TIMP2 Ϫ/Ϫ hearts at 3days ( Figure 7A ) and 1 week post-MI ( Figure 7B ) compared to WT. Expression analysis of MMPs that contribute to the collagenase activity showed that compared to WT hearts, MMP8 increased more significantly in the periinfarct, MMP13 in the peri-and noninfarct, and MT1-MMP in the infarct and periinfarct regions of TIMP2 Ϫ/Ϫ hearts at 3 days post-MI ( Figure 7C , i through iii). At 1 week post-MI, whereas expression of MMP8 decreased in WT hearts, it increased even further in TIMP2 Ϫ/Ϫ hearts (Figure 7D, i) . In addition, MMP13 was significantly greater in all regions, and MT1-MMP in the infarct and noninfarct regions of TIMP2 Ϫ/Ϫ -MI hearts ( Figure 7D , ii and iii). Collectively, this marked elevation in expression and activity of collagenases in TIMP2 Ϫ/Ϫ -MI hearts could explain the aberrant degradation of the ECM collagen fibers and adverse LV remodeling in these mice.
MT1-MMP was one of the collagenases that was upregulated in TIMP2-MI myocardium and is potently inhibited by TIMP2. 29 MT1-MMP is a membrane-bound MMP, and, as such, we examined the levels and the activity of this protease in the membrane fraction of the myocardium. We confirmed the purity of the membrane protein fractionation by blotting for a membrane protein (Toll-like receptor-4) as a positive control and a cytoplasmic protein (caspase 3) as a negative control (Online Figure III) . Coomassie blue staining was used as the loading control. Western blot analysis showed significantly higher MT1-MMP levels in the infarct and periinfarct regions of TIMP2 Ϫ/Ϫ myocardial tissue at 3 days (Figure 8A , ii) and 1 week post-MI ( Figure 8A , ii). We hypothesized that in the absence of TIMP2, activity of MT1-MMP would further increase. Using the antibody-based Biotrak activity assay, which measures the activity specific to MT1-MMP without disrupting the MMP-TIMP interactions, we found that MI resulted in a rise in MT1-MMP activity in both genotypes ( Figure 8B ). However, this rise was significantly greater in the peri-and noninfarct regions of TIMP2 Ϫ/Ϫ hearts at 3 days and in the infarct and periinfarct regions at 1 week post-MI. We further confirmed that the detected activity is specific to MT1-MMP by demonstrating that recombinant TIMP2 completely blocked this activity, whereas recombinant TIMP1, which does not inhibit MT-MMPs, 30 did not affect its activity ( Figure 8B ).
Discussion
MI triggers alterations in the structure and composition of the myocardial ECM including breakdown of collagen fibers leading to adverse myocardial remodeling. 2, 28, 31 TIMPs are physiological inhibitors of MMPs, the enzymes that degrade ECM proteins, and as such their function is critical in the outcome of ECM turnover and remodeling in health and in disease. 3 Among TIMPs, TIMP2 and its role in development and progression of cardiomyopathy is the least studied. Particularly, because TIMP2 has 2 opposing functions, as an activator and an inhibitor of MMPs, it is quite intriguing to determine how alterations in TIMP2 levels can impact the tissue response to disease. In this study, we demonstrate that TIMP2 is a critical regulator of cardiac response to MI. TIMP2 deficiency significantly deteriorates cardiac architecture and function following MI, resulting in exacerbated LV dilation, greater wall motion abnormalities, and overall systolic dysfunction compared to WT-MI mice. We identified MT1-MMP as one of the primary proteases whose activity is augmented in the absence of TIMP2.
MI altered TIMP levels in the heart, although an increase in mRNA was not always accompanied by an increase in the protein levels. Such mismatch between mRNA and protein of TIMPs has also been reported in a rat model of MI. 32 The dissociation between mRNA and protein levels suggests a posttranscriptional regulation of myocardial TIMP, whereas a rise in mRNA in the absence of a parallel increase in protein levels could be a compensatory attempt by the tissue to replace the loss of the corresponding protein.
Despite the markedly increased TIMP1 protein levels in TIMP2 Ϫ/Ϫ -MI, these mice exhibited exacerbated infarct expansion and LV dilation and dysfunction compared to WT-MI. TIMP1 can inhibit a wide range of MMPs, but is a poor inhibitor of MT1-MMP. 30, 33 This further supports a key role for MT1-MMP in mediating the severe cardiomyopathy in TIMP2 Ϫ/Ϫ -MI mice. In addition, the upregulation of TIMP1 and MMP9 in TIMP2 Ϫ/Ϫ -MI hearts are consistent with the more severe inflammation in these hearts as TIMP1 and MMP9 levels are often used as markers of severity of inflammation in different inflammatory diseases including sepsis. 34 In addition, the heightened inflammation in the TIMP2 Ϫ/Ϫ -MI hearts could also explain the significantly higher levels of MMP8 and MMP9 in these hearts, the 2 MMPs that are produced by neutrophils, which can in turn facilitate neutrophil migration. 35 The elevated MMP9 levels could also contribute to the exacerbated LV dilation in TIMP2 Ϫ/Ϫ -MI hearts because MMP9-deficient mice exhibit less LV dilation. 36 MI exerts localized tissue damage in the heart; hence, examining the region-specific alterations (infarct, peri-and noninfarct) is critical in determining the underlying mechanism for disease progression. Remodeling in the infarct and periinfarct regions determine the final outcome of infarct remodeling and expansion. 2 We found that with the exception of TIMP1, TIMP levels were generally reduced, whereas MMP levels and proteolytic activities were elevated in the infarct and periinfarct regions early post-MI. Consistent with the greater regional biochemical and structural abnormalities in the TIMP2 Ϫ/Ϫ myocardium, localized LV wall motion abnormalities were also greater in the postinfarct TIMP2 Ϫ/Ϫ mice. Disturbance of the proteolytic balance and the resulting adverse ECM remodeling in the noninfarct region impacts the global contractility of the heart post-MI. Our data demonstrate that TIMP2 deficiency negatively influences the periinfarct and noninfarct myocardium, resulting in infarct expansion and decreased global myocardial contractility.
TIMP2 and MT1-MMP are involved in cell surface activation of pro-MMP2 through formation of a trimolecular complex, MT1-MMP/TIMP2/pro-MMP2. 13, 14 MMP2 is a gelatinase and collagenase 37 that has been linked to a number of cardiomyopathies. 4, 5, 15 TIMP2 deficiency abolished MMP2 activation, which was markedly increased in WT-MI infarct and periinfarct myocardium. Despite a significant increase in the activity of MT1-MMP, no cleavage of pro-MMP2 to its 62-kDa form was detected in the TIMP2 Ϫ/Ϫ myocardium. Biochemical studies have shown that pro-MMP2 can be activated by MT2-MMP and MT3-MMP in a TIMP2-independent fashion. 38 Our study clearly demonstrates that presence of TIMP2 is absolutely essential for the cell surface activation of pro-MMP2 in the heart. Given the reported contribution of MMP2 is different cardiomyopathies, 4,5,15,39 -42 the exacerbated LV dilation and dysfunction in TIMP2 Ϫ/Ϫ -MI mice, despite the lack of MMP2 activation, is quite intriguing. Interestingly, increased MMP2 activation has been reported to underlie post-MI LV rupture, 43 and consistent with its lack of activation in TIMP2 Ϫ/Ϫ -MI hearts, we did not observe an elevated rate of LV rupture in these mice despite their severe remodeling and dysfunction compared to WT hearts post-MI.
Using the novel imaging technique of SHG and multiphoton microscopy, we detected aberrant ECM remodeling characterized by lower density and enhanced disarray of the collagen fibers in the infarct and noninfarct regions of the TIMP2 Ϫ/Ϫ -MI hearts. The advantage of SHG over other imaging techniques is that it uses minimally manipulated tissue (unfixed and unstained), hence providing a more physiological presentation of the collagen fiber quality and arrangements. The enhanced collagen fiber breakdown in TIMP2-deficient myocardium was confirmed by the reduced content of fibrillar collagen in the infarct and periinfarct regions compared to parallel WT group. The aberrant degradation of the ECM structure was brought about by enhanced collagenase activity in TIMP2 Ϫ/Ϫ -MI hearts attributable to increased MT1-MMP activity, whereas other MMPs (MMP8, MMP9, and MMP13) could also contribute to this process. We used BioTrak MT1-MMP-specific activity assay to demonstrate the elevated activity of MT1-MMP in TIMP2deficient myocardium, which was inhibited by rhTIMP2 but not by rhTIMP1, further demonstrating the TIMP2 dependence of this increased activity.
The marked increase in MT1-MMP activity in TIMP2 Ϫ/Ϫ -MI hearts resulted from the increased protein levels, as well as the absence of the inhibitory function of TIMP2, which potently inhibits MT1-MMP. 29, 44 In addition, in the absence of TIMP2, the fraction of MT1-MMP that would be engaged in the trimolecular complex and activation of pro-MMP2 remains available to perform its collagenolytic function. MT1-MMP is a potent collagenase, 45, 46 which also targets other ECM components, such as fibronectin, 47, 48 laminin, 47, 49 and proteoglycans. 50, 51 In addition, MT1-MMP can mediate activation of other pro-MMPs, such as MMP13 (collagenase-3), 52 which is also a potent collagenase with broad substrate specificity, thereby amplifying the collagen-degradation process. Recently, it has been reported that MT1-MMP overexpression results in a severe dilated cardiomyopathy. 46 In addition, MT1-MMP is elevated in fibroblasts from patients with cardiomyopathies and has been shown to contribute to heart disease. 53 Our study provides evidence that TIMP2 can regulate the activity of MT1-MMP, thereby serving as a potential therapeutic target for heart disease. Our findings need to be confirmed in females because the ECM regulatory genes have been shown to exhibit a sex-dependent pattern in experimental models of heart disease. 54 In conclusion, this study is the first to demonstrate that TIMP2 is a key molecule in cardiac recovery from MI and that the MMP-inhibitory function of TIMP2 is more critical than its MMP2-activating role in determining the fate of the myocardium in heart disease. Hence, TIMP2 replenishment in diseased myocardium could provide a potential therapy in reducing or preventing disease progression.
